Diabetes
Conditions
Brief summary
The investigators designed this prospective, randomized control study to compare the efficacy and safety between the basal insulin glargine therapy and metformin-based OADs after correction of the glucose toxicity with a short period of intensive insulin therapy.
Detailed description
Detailed Description: OBJECTIVE-Type 2 diabetes is associated with defects in insulin secretion and insulin sensitivity. Hyperglycemia may aggravate these defects, a feature known as glucose toxicity. Previous studies have shown that acute correction of hyperglycemia in subjects with long-standing type 2 diabetes gives only short-term improvement in glycemic control after discontinuation of insulin. The current study attempts to identify whether basal insulin glargine or metformin-based OADs for further management would have a long-term benefit in newly diagnosed type 2 diabetes after short-term intensive insulin therapy. RESEARCH DESIGN AND METHODS-Newly diagnosed type 2 diabetic patients (fasting blood glucose \>200 mg/dL or random blood glucose \>300 mg/dL) will be hospitalized and treated with intensive insulin injection for 10 to 14 days. HbA1c were measured before intensive insulin injection. After discharge, patients will be randomized to receive basal insulin injection or metformin-based OADs for further management. Patients will be followed in our clinics and adjust their medication according to their blood glucose levels. HbA1c were measured 6 months later.After the six-month intervention, these patients were continually followed up for another six months. Subjects received an oral glucose tolerance test (OGTT) after the intensive insulin therapy and at the end of the 6th and 12th month. EXPECTED RESULTS-We will expect that basal insulin glargine,compared with metformin-based OAD treatment,could more effectively maintain adequate glycemic control in newly diagnosed type 2 diabetes after short-term intensive insulin therapy.
Interventions
DRUGmetformin-based Oral Antidiabetic Drugs
DRUGGlargine
Sponsors
Chongqing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Newly diagnosed type 2 diabetic patients. 2. Drug naïve, with severe hyperglycemia (fasting plasma glucose\>11.1mmol/L or random plasma glucose \>16.7mmol/L) 3. Those who age between 30 and 70 years old and can inject insulin by themselves.
Exclusion criteria
1. Established type 1 diabetes or positive anti-glutamic acid decarboxylase antibody; 2. Malignancy, pregnancy or lactating; 3. History of ketoacidosis; 4. Hepatic dysfunction with alanine aminotransferase 2.5 times higher than the upper limit of normal; serum creatinine \>2 mg/dl; 5. Poor blood pressure control (SBP\>180mmHg or DBP \>110mmHg); 6. Definite coronary artery disease, heart failure, left ventricular hypertrophy; 7. Severe anemia; acute or severe chronic diabetes complications; 8. BMI\<18 kg/m2 or ≥41kg/m2; 9. History of alcohol abuse or drug abuse; 10. Mental disorder and other endocrine disorders; dysfunction of digestion and absorption; 11. Chronic diseases need long-term glucocorticoid treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycosylated Hemoglobin (HbA1c) at month 6 | month 6 |
| Change From Baseline in Glycosylated Hemoglobin at month 6 | Baseline and month 6 |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants With Glycosylated Hemoglobin ≤ 7% | month 6 |
| Number of Participants With Glycosylated Hemoglobin ≤ 6.5% | month 6 |
| Fasting Plasma Glucose at week 2 | week 2 |
| Fasting Plasma Glucose at week 4 | week 4 |
| Fasting Plasma Glucose at week 8 | week 8 |
| Fasting Plasma Glucose at week 12 | week 12 |
| Fasting Plasma Glucose at week 16 | week 16 |
| Fasting Plasma Glucose at week 20 | week 20 |
| Fasting Plasma Glucose at week 24 | week 24 |
| Fasting Plasma Glucose at week 32 | week 32 |
| Fasting Plasma Glucose at week 40 | week 40 |
| Fasting Plasma Glucose at week 48 | week 48 |
| Homeostasis model assessment (HOMA)-β at month 6 | month 6 |
| Insulinogenic index at month 6 | month 6 |
| HOMA-IR at month 6 | month 6 |
| Matsuda index at month 6 | month 6 |
| Basal disposition index at month 6 | month 6 |
| Glycosylated Hemoglobin at month 12 | month 12 |
| Homeostasis model assessment (HOMA)-β at month 12 | month 12 |
| Insulinogenic index at month 12 | month 12 |
| HOMA-IR at month 12 | month 12 |
| Matsuda index at month 12 | month 12 |
| Basal disposition index at month 12 | month 12 |
| Early-phase disposition index at month 12 | month 12 |
| Diabetes Treatment Satisfaction Questionnaire status (DTSQs) version score | month 6 |
| DTSQs score at month 12 | month 12 |
| Audit of Diabetes Dependent Quality of Life (ADDQoL) score | month 6 |
| ADDQoL score at month 12 | month 12 |
| Cost at month 6 | month 6 |
| Number of Participants with Hypoglycemia | up to 6 month |
| Number of hypoglycemia episodes | up to 6 month |
| Number of Participants with severe Hypoglycemia | up to 6 month |
| Number of severe hypoglycemia episodes | up to 6 month |
| Change From Baseline in Body Weight (month 6) | Baseline and month 6 |
| Change From Baseline in Body Weight (month 12) | Baseline and month 12 |
| Early-phase disposition index at month 6 | month 6 |
| Change From Baseline in Glycosylated Hemoglobin at month 12 | Baseline and month 12 |
Countries
China
Outcome results
None listed